Editas Medicine Q2 2024 GAAP EPS $(0.82) Misses $(0.70) Estimate, Sales $513.000K Miss $5.083M Estimate
Portfolio Pulse from Benzinga Newsdesk
Editas Medicine reported its Q2 2024 financial results, with a GAAP EPS of $(0.82), missing the estimate of $(0.70). Sales were $513,000, significantly below the $5.083 million estimate.
August 07, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Editas Medicine reported disappointing Q2 2024 financial results, with both EPS and sales missing estimates. GAAP EPS was $(0.82) compared to the $(0.70) estimate, and sales were $513,000 versus the $5.083 million estimate.
The significant miss on both EPS and sales estimates is likely to negatively impact Editas Medicine's stock price in the short term. Investors typically react unfavorably to such earnings reports, especially when the misses are substantial.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100